Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. For more information, please visit www.hepionpharma.com.
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment ConferenceSep 10, 2019 at 4:15 PM EDT
ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity ConferenceMay 2, 2019 at 1:30 PM EDT